目的探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺酸性磷酸酶(prostatic acid phosphatase,PAP)与前列腺癌患者饮食结构的相关性,为前列腺癌患者饮食结构提供依据。方法选取2014年2月至2016年12月四川大学华西医院泌尿...目的探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺酸性磷酸酶(prostatic acid phosphatase,PAP)与前列腺癌患者饮食结构的相关性,为前列腺癌患者饮食结构提供依据。方法选取2014年2月至2016年12月四川大学华西医院泌尿外科收治的180例前列腺癌患者为研究对象,作为试验组,同期选择120例前列腺炎患者为对照组,采用发光法检测PSA,放射免疫法检测PAP,比较两组PSA、PAP水平,并采用膳食结构问卷调查对两组对象进行饮食结构分组,分析PSA、PAP与饮食结构的相关性。结果试验组PSA、PAP依次是(10.54±1.35)ng/mL、(14.08±0.94)μg/L,均明显高于对照组(5.02±0.83)ng/mL、(6.56±0.79)μg/L,差异有统计学意义(P<0.05);试验组面粉、谷类摄入量明显低于对照组,畜禽肉类、食用油及盐摄入量明显高于对照组(P<0.05);经因子分析得出5种膳食模型:优质蛋白质模式、地中海模式、传统模式、调味品模式和西方模式,分析此5种饮食模式与PSA、PAP水平关系,显示PSA与饮食模式1、模式2呈负相关(B=-0.387,P=0.027;B=-3.812,P<0.001),与模式4、模式5呈正相关(B=0.763,P<0.001;B=0.531,P<0.001),与模式3无明显相关性(B=0.483,P=0.083);PAP与饮食模式无明显相关性(P>0.05)。结论前列腺癌患者多进食高脂肪、高热量、低纤维素食品,以西方膳食结构、调味品膳食结构为主,其机体PSA、PAP明显升高,且PSA与西方膳食结构、调味品膳食结构呈正相关,与优质蛋白质膳食结构、地中海膳食结构呈负相关,PAP则无明显相关性。展开更多
The skeleton is the most common metastatic organ in patients with prostate cancer （PCa）. Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed ...The skeleton is the most common metastatic organ in patients with prostate cancer （PCa）. Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed this study to assess the expression patterns of serum miR-141 in patients with bone-metastatic PCa. Serum samples were collected to measure the miR-141 level in 56 patients, including six with benign prostatic hyperplasia （BPH）, 20 with localized PCa and 30 with bone-metastatic PCa （10 with hormone-naive PCa, 10 with hormone-sensitive PCa and 10 with hormone-refractory PCa）. A bone scan was performed for each patient with PCa to assess the number of bone lesions. The quantification of serum miR-141 levels was assayed by specific TaqMan qRT-PCR. The results showed that serum miR-141 levels were elevated in patients with bone metastasis （P〈O.O01）. There was no statistically significant difference in the serum miR-141 levels between patients with BPH and patients with localized PCa. Using Kendall＇s bivariate correlation test, both the Gleason score and the number of bone-metastatic lesions were found to correlate with serum miR-141 levels （P=0.012 and P〈O.O01, respectively）. The serum miR-141 level was found to be positively correlated with alkaline phosphatase （ALP） level in patients with skeletal metastasis, using Pearson＇s bivariate correlation test. No relationship was found between the serum miR-141 level and the serum prostate-specific antigen （PSA） level. We concluded that serum miR-141 levels are elevated in patients with bone-metastatic PCa and that patients with higher levels of serum miR-141 developed more bone lesions. Furthermore, serum miR-141 levels are correlated with serum ALP levels but not serum PSA levels.展开更多
文摘目的探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺酸性磷酸酶(prostatic acid phosphatase,PAP)与前列腺癌患者饮食结构的相关性,为前列腺癌患者饮食结构提供依据。方法选取2014年2月至2016年12月四川大学华西医院泌尿外科收治的180例前列腺癌患者为研究对象,作为试验组,同期选择120例前列腺炎患者为对照组,采用发光法检测PSA,放射免疫法检测PAP,比较两组PSA、PAP水平,并采用膳食结构问卷调查对两组对象进行饮食结构分组,分析PSA、PAP与饮食结构的相关性。结果试验组PSA、PAP依次是(10.54±1.35)ng/mL、(14.08±0.94)μg/L,均明显高于对照组(5.02±0.83)ng/mL、(6.56±0.79)μg/L,差异有统计学意义(P<0.05);试验组面粉、谷类摄入量明显低于对照组,畜禽肉类、食用油及盐摄入量明显高于对照组(P<0.05);经因子分析得出5种膳食模型:优质蛋白质模式、地中海模式、传统模式、调味品模式和西方模式,分析此5种饮食模式与PSA、PAP水平关系,显示PSA与饮食模式1、模式2呈负相关(B=-0.387,P=0.027;B=-3.812,P<0.001),与模式4、模式5呈正相关(B=0.763,P<0.001;B=0.531,P<0.001),与模式3无明显相关性(B=0.483,P=0.083);PAP与饮食模式无明显相关性(P>0.05)。结论前列腺癌患者多进食高脂肪、高热量、低纤维素食品,以西方膳食结构、调味品膳食结构为主,其机体PSA、PAP明显升高,且PSA与西方膳食结构、调味品膳食结构呈正相关,与优质蛋白质膳食结构、地中海膳食结构呈负相关,PAP则无明显相关性。
文摘The skeleton is the most common metastatic organ in patients with prostate cancer （PCa）. Non-invasive biomarkers that can facilitate the detection and monitoring of bone metastases are highly desirable. We designed this study to assess the expression patterns of serum miR-141 in patients with bone-metastatic PCa. Serum samples were collected to measure the miR-141 level in 56 patients, including six with benign prostatic hyperplasia （BPH）, 20 with localized PCa and 30 with bone-metastatic PCa （10 with hormone-naive PCa, 10 with hormone-sensitive PCa and 10 with hormone-refractory PCa）. A bone scan was performed for each patient with PCa to assess the number of bone lesions. The quantification of serum miR-141 levels was assayed by specific TaqMan qRT-PCR. The results showed that serum miR-141 levels were elevated in patients with bone metastasis （P〈O.O01）. There was no statistically significant difference in the serum miR-141 levels between patients with BPH and patients with localized PCa. Using Kendall＇s bivariate correlation test, both the Gleason score and the number of bone-metastatic lesions were found to correlate with serum miR-141 levels （P=0.012 and P〈O.O01, respectively）. The serum miR-141 level was found to be positively correlated with alkaline phosphatase （ALP） level in patients with skeletal metastasis, using Pearson＇s bivariate correlation test. No relationship was found between the serum miR-141 level and the serum prostate-specific antigen （PSA） level. We concluded that serum miR-141 levels are elevated in patients with bone-metastatic PCa and that patients with higher levels of serum miR-141 developed more bone lesions. Furthermore, serum miR-141 levels are correlated with serum ALP levels but not serum PSA levels.
